RT Book, Section
A1 Papadakis, Maxine A.
A1 McPhee, Stephen J.
A1 Rabow, Michael W.
A1 McQuaid, Kenneth R.
SR Print(0)
ID 1193123799
T1 Viral & Rickettsial Infections Year in Review
T2 Current Medical Diagnosis & Treatment 2023
YR 2023
FD 2023
PB McGraw-Hill Education
PP New York, NY
SN 9781264687343
LK accessmedicine.mhmedical.com/content.aspx?aid=1193123799
RD 2023/12/01
AB A  novel  oral  polio  vaccine  type  2  (nOPV2)  has  been  developed  in  response  to  the  ongoing  circulating  vaccine-derived  type  2  poliovirus  outbreaks  and  has  been  shown  to  be  safe  and  immunogenic  in  previously  immunized  adults.  Studies  have  shown  that  nOPV2  is  more  genetically  stable  than  the  mOPV2  and  therefore  less  prone  to  reverting  to  neurovirulence.  The  nOPV2  was  recommended  for  initial  use  under  the  World  Health  Organization’s  Emergency  Use  Listing  Procedure  in  November  2020.